论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
高强度聚焦超声联合米非司酮治疗后行宫腔镜下子宫肌瘤切除术治疗 2 型黏膜下肌瘤:1 例报告及文献复习
Authors Li J , Yang L, Wang Y , He M, Zhu H , Huang Y
Received 27 March 2025
Accepted for publication 16 July 2025
Published 4 August 2025 Volume 2025:17 Pages 2401—2412
DOI https://doi.org/10.2147/IJWH.S530879
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Everett Magann
Junjie Li,1,2,* Leilei Yang,2,* Yan Wang,2 Min He,3 Hongqiu Zhu,2 Yefang Huang2
1Traditional Chinese Medicine Department, Hunan University of Medicine General Hospital, Hunan, Huaihua, 418000, People’s Republic of China; 2Gynaecology, Hospital of Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu, 610072, People’s Republic of China; 3State Key Laboratory of Ultrasound in Medicine and Engineering, Chongqing Medical University, Chongqing, 400016, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yefang Huang, Email huangyefang@cdutcm.edu.cn
Abstract: Hysteroscopic myomectomy is the first-line treatment for the removal of submucosal myoma in women facing fertility requirements. However, in the face of large diameter type 2 submucosal myoma, patients are at greater risk of complications such as uterine perforation and fluid overload during hysteroscopy. When the diameter of type 2 submucous myoma is greater than 4cm, the three-phase treatment of high intensity focused ultrasound (HIFU), drugs and hysteroscopy is effective and safe. We shared a case of a 30-year-old non-pregnant woman, who had a history of uterine submucous myoma for more than 4 years with symptoms of heavy menstruation, prolonged menstruation and secondary severe anemia. The patient’s initial pelvic magnetic resonance results suggested a type 2 uterine submucous myoma with a diameter of more than 4cm. We first performed HIFU on the patient, followed by the patient’s oral intake of mifepristone tablets for 3 months, and prior to hysteroscopic surgery, the patient’s fibroid type was shifted to type 0, and finally successfully completed hysteroscopic myomectomy (HM). Finally, we conclude that when the diameter of type 2 submucosal myoma exceeds 4 cm, preoperative application of HIFU combined with drug treatment should be considered to maximize the reduction of fibroids, improve symptoms such as anemia and dysmenorrhea, reduce the time required for hysteroscopic surgery, and improve the safety of surgery.
Keywords: high intensity focused ultrasound, hysteroscopic myomectomy, mifepristone, submucous myoma of uterus, uterine fibroid